Shots:
- Exicure to receive a $20M up front and will be eligible to receive ~$1B in option exercise fees and milestones along with royalties, if Ipsen exercises its option
- Exicure will be responsible for the discovery and pre-clinical development activities while Ipsen will lead further development and commercialization of the licensed product after exercising the option
- Ipsen obtains exclusive options to license SNA based therapeutics for Huntington’s disease and Angelman syndrome based on two collaboration programs
Click here to to read full press release/ article | Ref: Ipsen | Image: Business Wire
The post Ipsen Signs an Exclusive Collaboration with Exicure to Develop SNA-Based Therapeutics for Rare Neurodegenerative Disorders first appeared on PharmaShots.
